One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients

BACKGROUND: Despite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited evidence exists to support these recommendations. The present study was designed to examine the safety and effectiveness of 1-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandzari, David E., Kirtane, Ajay J., Windecker, Stephan, Latib, Azeem, Kedhi, Elvin, Mehran, Roxana, Price, Matthew J., Abizaid, Alexandre, Simon, Daniel I., Worthley, Stephen G., Zaman, Azfar, Choi, James W., Caputo, Ronald, Kanitkar, Mihir, McLaurin, Brent, Potluri, Srinivasa, Smith, Timothy, Spriggs, Douglas, Tolleson, Thaddeus, Nazif, Tamim, Parke, Maria, Lee, Lilian C., Lung, Te-Hsin, Stone, Gregg W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665241/
https://www.ncbi.nlm.nih.gov/pubmed/33167705
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.009565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665241/
https://www.ncbi.nlm.nih.gov/pubmed/33167705
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.009565

Ejemplares similares